Qiagen Posts a Mixed Quarter - Analyst Blog
November 03 2011 - 9:00AM
Zacks
Qiagen (QGEN)
reported adjusted EPS of 24 cents in the third quarter of fiscal
2011, beating the Zacks Consensus Estimate of 21 cents but a penny
lower than the prior-year quarter.
Net sales in the quarter stood at
$288.9 million, up 5% year over year (up 1% at constant exchange
rates or CER) but lagged the Zacks Consensus Estimate of $291
million. However, excluding the contributions from Cellestis (since
August 29) and Ipsogen (since July 12), total sales declined 3% at
CER.
Under the product categories,
Consumables and related revenues (accounting for 87% of net sales
in the quarter) remained flat year over year at CER, while
instrumentation revenues (accounting for the rest) increased more
than 8%, primarily due to targeted initiatives across the company’s
broad product range. QIAsymphony placements also contributed to the
growth through higher sales. Instrument sales also reflected a
shift toward ‘reagent rental agreements’ and similar
arrangements.
Region wise, Americas (48% of
revenues) witnessed a 5% decline impacted by the timing of a
national HPV (human papilloma virus) test tender delivery. However,
revenues from Europe- Middle East-Africa (33% of sales) and
Asia-Pacific /Japan (17% of sales) increased 15% and 19% at CER,
respectively. Europe benefited from the ongoing rollout of the
QIAsymphony RGQ automation system as well as higher contributions
from Molecular Diagnostics and Academia in Northern Europe. On the
other hand, renewed growth impulses led to a double-digit growth in
China while Japan demonstrated double-digit sales expansion
throughout the customer base.
Segments
Qiagen primarily derives revenues
from molecular diagnostics, applied testing, pharma and academia,
which represented 46%, 7%, 21% and 26% of total sales,
respectively, during the quarter. Molecular diagnostics sales
registered a 5% drop at CER. Despite recording higher Profiling
sales, the decline was due to the unfavorable timing of non-US
national HPV tender in Prevension.
Sales derived from applied testing
remained unchanged at CER, primarily driven by strong demand for
consumable products used for the implementation of new forensic
standards and human identification products in Europe and
Japan.
Pharma sales rose 6% at CER based
on initiatives taken during the quarter to accelerate sales of
products used in drug discovery and development. Academia witnessed
a 7% increase in net sales.
Qiagen has adopted several
strategic initiatives in the global Sample & Assay Technologies
market in order to deliver stronger performance in the second half
of 2011 as well as for 2012 and beyond. The company is currently
focusing on innovation and geographic expansion to drive organic
growth.
Outlook
For 2011, Qiagen reaffirmed its
revenue guidance. It expects to report a 3% growth in net sales at
CER. Moreover, for the full year, adjusted EPS is expected to be
96-97 cents (earlier guidance being 96 cents) at CER. For the
second half of 2011, Qiagen expects total sales growth of
approximately 7% at CER, of which organic revenue will account for
half of the growth.
Companion diagnostics is currently
gaining significant traction and peers of Qiagen like
Myriad Genetics (MYGN) are establishing themselves
as strong players in the companion diagnostic market. However,
Qiagen is adopting an aggressive acquisition strategy to widen its
scope and strengthen its position in the competitive landscape
compared to other major players like Life
Technologies (LIFE) and Sigma-Aldrich
(SIAL) .
Qiagen currently retains a
short-term Zacks#3 (Hold) Rank, which also reflects our ‘Neutral’
recommendation on the stock over the long term.
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
SIGMA ALDRICH (SIAL): Free Stock Analysis Report
Zacks Investment Research
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From May 2024 to Jun 2024
(MM) (NASDAQ:SIAL)
Historical Stock Chart
From Jun 2023 to Jun 2024